JP2020529995A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529995A5
JP2020529995A5 JP2020505367A JP2020505367A JP2020529995A5 JP 2020529995 A5 JP2020529995 A5 JP 2020529995A5 JP 2020505367 A JP2020505367 A JP 2020505367A JP 2020505367 A JP2020505367 A JP 2020505367A JP 2020529995 A5 JP2020529995 A5 JP 2020529995A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
behavior
change
composition according
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/071120 external-priority patent/WO2019025588A1/en
Publication of JP2020529995A publication Critical patent/JP2020529995A/ja
Publication of JP2020529995A5 publication Critical patent/JP2020529995A5/ja
Priority to JP2023136283A priority Critical patent/JP2023159354A/ja
Pending legal-status Critical Current

Links

JP2020505367A 2017-08-03 2018-08-03 行動の変化の治療方法 Pending JP2020529995A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023136283A JP2023159354A (ja) 2017-08-03 2023-08-24 行動の変化の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17382545 2017-08-03
EP17382545.6 2017-08-03
EP17382544 2017-08-03
EP17382544.9 2017-08-03
EP18382299 2018-04-30
EP18382299.8 2018-04-30
PCT/EP2018/071120 WO2019025588A1 (en) 2017-08-03 2018-08-03 METHODS OF TREATING ALTERATIONS IN BEHAVIOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023136283A Division JP2023159354A (ja) 2017-08-03 2023-08-24 行動の変化の治療方法

Publications (2)

Publication Number Publication Date
JP2020529995A JP2020529995A (ja) 2020-10-15
JP2020529995A5 true JP2020529995A5 (enExample) 2021-09-16

Family

ID=63077881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505367A Pending JP2020529995A (ja) 2017-08-03 2018-08-03 行動の変化の治療方法
JP2023136283A Pending JP2023159354A (ja) 2017-08-03 2023-08-24 行動の変化の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023136283A Pending JP2023159354A (ja) 2017-08-03 2023-08-24 行動の変化の治療方法

Country Status (23)

Country Link
US (2) US20200323828A1 (enExample)
EP (2) EP4512473A3 (enExample)
JP (2) JP2020529995A (enExample)
KR (2) KR102685898B1 (enExample)
CN (1) CN110996949A (enExample)
AU (2) AU2018309372B2 (enExample)
BR (1) BR112020000827A2 (enExample)
CA (1) CA3071804A1 (enExample)
DK (1) DK3661510T3 (enExample)
ES (1) ES3001085T3 (enExample)
FI (1) FI3661510T3 (enExample)
HR (1) HRP20241716T1 (enExample)
HU (1) HUE069697T2 (enExample)
IL (1) IL272092B1 (enExample)
LT (1) LT3661510T (enExample)
MX (2) MX2020001323A (enExample)
MY (1) MY204406A (enExample)
PH (1) PH12020500211A1 (enExample)
PL (1) PL3661510T3 (enExample)
RS (1) RS66336B1 (enExample)
SG (1) SG11202000077RA (enExample)
SI (1) SI3661510T1 (enExample)
WO (1) WO2019025588A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102646126B1 (ko) 2016-03-15 2024-03-11 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
BR112021016064A2 (pt) * 2019-03-20 2021-10-05 Oryzon Genomics, S.A. Métodos de tratamento do transtorno de personalidade borderline
CN120837494A (zh) * 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
EP4025210A1 (en) * 2019-09-03 2022-07-13 Oryzon Genomics, S.A. Vafidemstat for use in treating autism spectrum disorders
WO2021058024A1 (zh) * 2019-09-29 2021-04-01 南京明德新药研发有限公司 Lsd1抑制剂
CN118604352B (zh) * 2024-05-22 2025-08-01 暨南大学 Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2006279943B2 (en) 2005-08-10 2012-02-16 The Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
WO2008127734A2 (en) 2007-04-13 2008-10-23 The Johns Hopkins University Lysine-specific demethylase inhibitors
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びlsd1阻害剤
EP2467359A4 (en) 2009-08-18 2013-01-09 Univ Johns Hopkins (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
EA022459B1 (ru) 2010-04-20 2016-01-29 Университа' Дельи Студи Ди Рома "Ла Сапиенца" Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
CN103857393B (zh) 2011-03-25 2016-08-17 葛兰素史密斯克莱知识产权(第2号)有限公司 环丙基胺作为lsd1抑制剂
UA114406C2 (uk) 2011-08-09 2017-06-12 Такеда Фармасьютікал Компані Лімітед Похідні циклопропанаміну як інгібітори lsd1
BR112014003382B1 (pt) 2011-08-15 2022-03-15 University Of Utah Research Foundation Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os
WO2013033688A1 (en) 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP3736265A1 (en) 2011-10-20 2020-11-11 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
SI2776394T1 (sl) 2011-10-20 2019-05-31 Oryzon Genomics, S.A. Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1
CN105051005B (zh) 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
US9388123B2 (en) 2012-11-28 2016-07-12 Kyoto University LSD1-selective inhibitor having lysine structure
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
CN105555784B (zh) 2013-06-19 2019-03-15 犹他大学研究基金会 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
WO2015021128A1 (en) 2013-08-06 2015-02-12 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
WO2015089192A1 (en) 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
EP3102034A4 (en) 2014-02-07 2017-07-12 MUSC Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CA2941716A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1,1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
CN106459024B (zh) 2014-04-11 2019-11-05 武田药品工业株式会社 环丙胺化合物及其用途
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
SG11201609033TA (en) 2014-05-01 2016-11-29 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
MX375102B (es) 2014-05-30 2025-03-06 Ieo St Europeo Di Oncologia S R L Compuestos de ciclopropilamina como inhibidores de histona demetilasa
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
ES2812626T3 (es) 2014-06-27 2021-03-17 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
ES2905280T3 (es) 2014-07-03 2022-04-07 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
SG11201610975RA (en) 2014-07-03 2017-01-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
CN107074787B (zh) 2014-09-05 2020-10-27 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
PL3256218T3 (pl) 2015-02-12 2025-03-31 Imago Biosciences Inc. Inhibitor kdm1a i jego zastosowanie w terapii
CN106146361A (zh) 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
US20170001970A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
SI3371152T1 (sl) 2015-11-05 2021-06-30 Celgene Quanticel Research, Inc. Sestavki, ki vsebujejo lisin specifični demetilaze-1 inhibitor s piridinskim obročem in njihova uporaba pri zdravljenju raka
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
RU2726622C2 (ru) 2015-11-27 2020-07-15 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
KR102720551B1 (ko) 2015-12-29 2024-10-21 미라티 테라퓨틱스, 인크. Lsd1 억제제
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
US10590079B2 (en) 2016-03-01 2020-03-17 Novartis Ag Cyano-substituted indoles as LSD1 inhibitors
CN107200706A (zh) 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
CA3022561A1 (en) 2016-05-09 2017-11-16 Sridharan Rajagopal Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN106478639B (zh) 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
HUE063848T2 (hu) 2016-10-26 2024-02-28 Constellation Pharmaceuticals Inc LSD1 gátlók és gyógyászati alkalmazásaik
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
CN106831489B (zh) 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CN106928235A (zh) 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用

Similar Documents

Publication Publication Date Title
JP2020529995A5 (enExample)
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2018021046A5 (enExample)
JP2016163571A5 (enExample)
JP2017528507A5 (enExample)
JP2015523407A5 (enExample)
CN105636951A (zh) 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用
RS52256B (en) THERAPEUTIC USES OF COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITIES
JP2016512825A5 (enExample)
JP2015038135A5 (enExample)
JP2017506624A5 (enExample)
JP2016535795A5 (enExample)
JP2015083580A5 (enExample)
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2018537507A5 (enExample)
JP2013541583A5 (enExample)
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2015537009A5 (enExample)
JP2019536812A5 (enExample)
ME02474B (me) Terapijski režimi
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use